Oculis (NASDAQ:OCS) Rating Increased to Hold at Wall Street Zen

Key Points

• Oculis (NASDAQ:OCS) has been upgraded from a "sell" rating to a "hold" rating by Wall Street Zen, indicating a more positive outlook for the stock.
• HC Wainwright raised its price target for Oculis from $32.00 to $33.00, while Needham & Company set a $36.00 price objective, reflecting strong analyst confidence with an average rating of "Buy".
• The company reported a quarterly loss of ($0.59) EPS, missing expectations, but generated revenue of $0.25 million, surpassing analyst predictions.

Oculis (NASDAQ:OCS - Get Free Report) was upgraded by investment analysts at Wall Street Zen from a "sell" rating to a "hold" rating in a report released on Saturday.

A number of other research analysts have also issued reports on OCS. Needham & Company LLC assumed coverage on Oculis in a research report on Wednesday, August 27th. They set a "buy" rating and a $36.00 target price on the stock. HC Wainwright increased their target price on Oculis from $32.00 to $33.00 and gave the company a "buy" rating in a research report on Friday, August 22nd. Four investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus target price of $35.75.

Oculis Stock Performance

Shares of NASDAQ:OCS remained flat at $17.40 during midday trading on Friday. The stock had a trading volume of 16,163 shares, compared to its average volume of 14,121. Oculis has a 52-week low of $11.90 and a 52-week high of $23.08. The stock has a market cap of $759.68 million, a P/E ratio of -6.52 and a beta of 0.26. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.55 and a current ratio of 4.55. The company has a 50-day simple moving average of $17.58 and a two-hundred day simple moving average of $18.18.

Oculis (NASDAQ:OCS - Get Free Report) last announced its earnings results on Thursday, August 21st. The company reported ($0.59) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.53) by ($0.06). Oculis had a negative net margin of 13,958.12% and a negative return on equity of 90.31%. The business had revenue of $0.25 million for the quarter, compared to analysts' expectations of $0.14 million. As a group, research analysts forecast that Oculis will post -2.09 EPS for the current fiscal year.

Institutional Trading of Oculis

Hedge funds and other institutional investors have recently modified their holdings of the stock. Kestra Private Wealth Services LLC acquired a new stake in shares of Oculis in the 1st quarter worth $234,000. Bosun Asset Management LLC acquired a new stake in shares of Oculis in the 2nd quarter worth $378,000. Citadel Advisors LLC acquired a new stake in shares of Oculis in the 4th quarter worth $389,000. Marshall Wace LLP acquired a new stake in shares of Oculis in the 2nd quarter worth $393,000. Finally, Bank of America Corp DE increased its stake in shares of Oculis by 58.2% in the 4th quarter. Bank of America Corp DE now owns 28,980 shares of the company's stock worth $493,000 after acquiring an additional 10,667 shares during the last quarter. 22.30% of the stock is owned by institutional investors and hedge funds.

Oculis Company Profile

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.